| Primary |
| Hepatitis C |
67.6% |
| Drug Use For Unknown Indication |
9.8% |
| Hypertension |
3.7% |
| Product Used For Unknown Indication |
3.4% |
| Chronic Hepatitis C |
2.3% |
| Diabetes Mellitus |
1.6% |
| Depression |
1.4% |
| Hiv Infection |
1.3% |
| Anaemia |
1.1% |
| Epilepsy |
1.1% |
| Pregnancy |
1.1% |
| Pain |
0.9% |
| Cryoglobulinaemia |
0.7% |
| Hepatitis |
0.7% |
| Hepatitis C Virus |
0.7% |
| Amyotrophic Lateral Sclerosis |
0.5% |
| Gastrooesophageal Reflux Disease |
0.5% |
| Hypothyroidism |
0.5% |
| Insomnia |
0.5% |
| Asthma |
0.5% |
|
| Anaemia |
10.6% |
| Transmission Of Drug Via Semen |
9.9% |
| Weight Decreased |
8.6% |
| Abortion Spontaneous |
6.0% |
| Rash |
6.0% |
| Pancytopenia |
5.3% |
| Hepatitis |
4.6% |
| Sepsis |
4.6% |
| Thrombocytopenia |
4.6% |
| Vomiting |
4.6% |
| Overdose |
4.0% |
| Toxic Skin Eruption |
4.0% |
| Transaminases Increased |
4.0% |
| Delirium |
3.3% |
| Haemoglobin Decreased |
3.3% |
| Neutropenia |
3.3% |
| Photosensitivity Reaction |
3.3% |
| Pleural Effusion |
3.3% |
| Pregnancy |
3.3% |
| Quadriparesis |
3.3% |
|
| Secondary |
| Hepatitis C |
65.9% |
| Chronic Hepatitis C |
6.0% |
| Product Used For Unknown Indication |
5.6% |
| Drug Use For Unknown Indication |
3.7% |
| Hypertension |
3.5% |
| Depression |
3.1% |
| Hiv Infection |
1.9% |
| Anaemia |
1.4% |
| Pain |
1.2% |
| Hepatic Cirrhosis |
1.0% |
| Insomnia |
1.0% |
| Prophylaxis |
0.9% |
| Anxiety |
0.9% |
| Diabetes Mellitus |
0.8% |
| Nausea |
0.6% |
| Rash |
0.6% |
| Thrombocytopenia |
0.5% |
| Hepatitis |
0.5% |
| Ascites |
0.5% |
| Headache |
0.4% |
|
| White Blood Cell Count Decreased |
24.2% |
| Weight Decreased |
10.5% |
| Thrombocytopenia |
7.3% |
| Vomiting |
6.8% |
| Anaemia |
5.6% |
| Rash |
5.1% |
| Death |
4.7% |
| Weight Increased |
4.7% |
| Pancytopenia |
4.6% |
| Pyrexia |
4.2% |
| Pneumonia |
2.9% |
| Syncope |
2.6% |
| Pruritus |
2.3% |
| Platelet Count Decreased |
2.3% |
| Nausea |
2.2% |
| Neutropenia |
2.2% |
| Urinary Tract Infection |
2.1% |
| Renal Failure |
2.0% |
| Vision Blurred |
2.0% |
| Haemoglobin Decreased |
1.8% |
|
| Concomitant |
| Hepatitis C |
66.1% |
| Product Used For Unknown Indication |
7.0% |
| Hypertension |
6.7% |
| Hiv Infection |
3.5% |
| Diabetes Mellitus |
2.5% |
| Chronic Hepatitis C |
2.0% |
| Anaemia |
1.8% |
| Depression |
1.5% |
| Hypothyroidism |
1.1% |
| Anxiety |
1.0% |
| Urinary Tract Infection |
1.0% |
| Prophylaxis |
0.9% |
| Sleep Disorder |
0.8% |
| Pruritus |
0.7% |
| Gastrooesophageal Reflux Disease |
0.6% |
| Hepatic Cirrhosis |
0.6% |
| Insomnia |
0.6% |
| Type 2 Diabetes Mellitus |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
| Insulin Resistance |
0.6% |
|
| Anaemia |
12.3% |
| Rash |
10.9% |
| Vomiting |
10.0% |
| Nausea |
7.9% |
| Pruritus |
6.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.4% |
| Pyrexia |
5.2% |
| Thrombocytopenia |
5.0% |
| Asthenia |
4.2% |
| Rash Pruritic |
4.2% |
| Weight Decreased |
3.6% |
| Rash Maculo-papular |
3.3% |
| Pancytopenia |
3.1% |
| Death |
2.9% |
| Inappropriate Schedule Of Drug Administration |
2.9% |
| Neutropenia |
2.9% |
| Septic Shock |
2.9% |
| White Blood Cell Count Decreased |
2.7% |
| Drug Eruption |
2.5% |
| Fatigue |
2.1% |
|
| Interacting |
| Hepatitis C |
49.2% |
| Product Used For Unknown Indication |
12.7% |
| Drug Use For Unknown Indication |
11.9% |
| Diabetes Mellitus |
4.8% |
| Hepatitis |
4.8% |
| Hiv Infection |
4.8% |
| Herpes Zoster |
3.2% |
| Blood Pressure |
2.4% |
| Blood Pressure Increased |
2.4% |
| Varicose Vein |
1.6% |
| White Blood Cell Count Decreased |
1.6% |
| Epilepsy |
0.8% |
|
| Vision Blurred |
20.0% |
| Weight Decreased |
16.7% |
| Drug Interaction |
6.7% |
| Liver Function Test Abnormal |
6.7% |
| Neutropenia |
6.7% |
| Renal Failure Acute |
6.7% |
| White Blood Cell Count Decreased |
6.7% |
| Epilepsy |
3.3% |
| Hallucination, Auditory |
3.3% |
| Leg Amputation |
3.3% |
| Myocarditis |
3.3% |
| Pneumonia |
3.3% |
| Prothrombin Time Ratio Decreased |
3.3% |
| Stress Cardiomyopathy |
3.3% |
| Thrombocytopenia |
3.3% |
| Ulcerative Keratitis |
3.3% |
|
